Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of APD334-003 in Moderately to Severely Active Ulcerative Colitis
2015-002109-12Phase 2Completed
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etrasimod in autoimmune colitis, sponsored by Arena Pharmaceuticals, Inc. Primary endpoint: Long-term safety of APD334. Started Nov 2015; status: completed.
02
Drugs
etrasimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2015-002109-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002109-12.